Drug Profile


Alternative Names: GSK 3389404; ISIS GSK6 LRx

Latest Information Update: 30 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis
  • Developer GlaxoSmithKline
  • Class Antisense elements; Antisense oligonucleotides; Antivirals
  • Mechanism of Action Viral protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 01 Feb 2017 Phase-II clinical trials in Hepatitis B in Hong Kong (SC) (NCT03020745)
  • 16 Jan 2017 GlaxoSmithKline plans a phase II trial for Hepatitis B in Hong Kong (SC) (NCT03020745)
  • 01 Jan 2017 GlaxoSmithKline completes a phase I trial in Hepatitis B (In volunteers) in United Kingdom (SC) (NCT02647281)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top